Sarcomas are a heterogeneous group of tumors that show only moderate response to treatment. In this proposal, we build on our previous work using Positron Emission Tomography (PET) to contribute to the management of sarcoma patients. These studies are also a model for PET applications in other types of cancer.
The specific aims i n this proposal address three important areas where we will explore PET contributions to the treatment and evaluation of a patient with sarcoma. Using [F- 18]fluorodeoxyglucose (FDG) and PET, we will perform semi-quantitative imaging studies on patients to determine tumor metabolism. This baseline patient data will be correlated with patient outcome. This work will continue our evaluation of the ability for FDG PET derived tumor measures to assess and predict time to local tumor recurrence, metastasis, and death. Rigorous methods will be applied to determine the statistical significance of the differences between survival curves. Additionally, measures of tumor heterogeneity in FDG metabolism using specialized statistical image analysis techniques will also be correlated for their ability to predict tumor response and overall survival. In another specific aim, [C- 11 ]thymidine will be implemented as a direct measure of tumor proliferation to be predictive of chemotherapy response in patients receiving neoadjuvant chemotherapy for high grade sarcomas. The [C- 11]thymidine data will be compared directly to the clinical reports of percent tumor viability' at the time of resection following neoadjuvant chemotherapy. Another subgroup of sarcoma patients under study are those patients who undergo bone allograft placement in limb salvage surgery, for treatment of bony sarcomas. At the sites of union between graft and native bone, dense bony callous forms. However, the natural history of bone allograft healing and incorporation with respect to this callous is unclear. We hypothesize that the [F-18] PET bone scans will be sensitive for characterizing the normal allograft union process and can distinguish the pathological situations of graft nonunion versus tumor recurrence in this setting. The focus of these studies are to exploit the quantitative data and high level of spatial sensitivity in PET images to characterize tissue metabolism in specific situations facing sarcoma patients. These studies also serve as a model for study in other types of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA065537-07
Application #
6376106
Study Section
Diagnostic Radiology Study Section (RNM)
Project Start
1995-08-14
Project End
2005-05-31
Budget Start
2001-08-27
Budget End
2002-05-31
Support Year
7
Fiscal Year
2001
Total Cost
$453,214
Indirect Cost
Name
University of Washington
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wolsztynski, Eric; O'Sullivan, Finbarr; Keyes, Eimear et al. (2018) Positron emission tomography-based assessment of metabolic gradient and other prognostic features in sarcoma. J Med Imaging (Bellingham) 5:024502
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Eary, Janet F; Conrad, Ernest U; O'Sullivan, Janet et al. (2014) Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. J Bone Joint Surg Am 96:152-8
Yan, Jinchun; Jones, Robin L; Lewis, David H et al. (2013) Impact of (18)F-FDG PET/CT imaging in therapeutic decisions for malignant solitary fibrous tumor of the pelvis. Clin Nucl Med 38:453-5
Pollack, Seth M; Li, Yonqing; Blaisdell, Megan J et al. (2012) NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One 7:e32165
Pollack, Seth M; Jungbluth, Achim A; Hoch, Benjamin L et al. (2012) NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 118:4564-70
Hawe, David; Hernández Fernández, Francisco R; O'Suilleabháin, Liam et al. (2012) Kinetic Analysis of Dynamic Positron Emission Tomography Data using Open-Source Image Processing and Statistical Inference Tools. Wiley Interdiscip Rev Comput Stat 4:316-322
O'Sullivan, F; Wolsztynski, E; O'Sullivan, J et al. (2011) A statistical modeling approach to the analysis of spatial patterns of FDG-PET uptake in human sarcoma. IEEE Trans Med Imaging 30:2059-71
Eary, Janet F; Hawkins, Douglas S; Rodler, Eve T et al. (2011) (18)F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging 1:47-53
Eary, Janet F; Link, Jeanne M; Muzi, Mark et al. (2011) Multiagent PET for risk characterization in sarcoma. J Nucl Med 52:541-6

Showing the most recent 10 out of 30 publications